Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Originally incorporated as Americus Funding Corporation in December 1987, the company changed its name to NeoTherapeutics Inc in August 1996. However, on 11th December 2002, NeoTherapeutics changed its name to Spectrum Pharmaceuticals. Spectrum is an oncology focused specialty pharmaceutical company. Its core expertise is the in-licensing, clinical development and commercialisation of oncology drugs.